NCT03098797View on ClinicalTrials.gov

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

October 5, 2018

Study Completion Date

October 11, 2021

Conditions
Barth Syndrome
Interventions
DRUG

Elamipretide

40 mg daily subcutaneous injection for 12 weeks

DRUG

Placebo

daily subcutaneous injection for 12 weeks

Trial Locations (1)

21287

McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore

All Listed Sponsors
lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT03098797 - A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome | Biotech Hunter | Biotech Hunter